PNC Financial Services Group Inc. decreased its holdings in shares of Amedisys, Inc. (NASDAQ:AMED – Free Report) by 2.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 6,486 shares of the health services provider’s stock after selling 186 shares during the period. PNC Financial Services Group Inc.’s holdings in Amedisys were worth $617,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Arizona State Retirement System lifted its stake in Amedisys by 1.5% in the third quarter. Arizona State Retirement System now owns 9,284 shares of the health services provider’s stock valued at $867,000 after buying an additional 141 shares during the period. Barclays PLC boosted its stake in Amedisys by 152.6% during the 3rd quarter. Barclays PLC now owns 127,565 shares of the health services provider’s stock worth $11,915,000 after acquiring an additional 77,074 shares during the last quarter. New York Life Investment Management LLC boosted its stake in Amedisys by 129.7% during the 3rd quarter. New York Life Investment Management LLC now owns 76,843 shares of the health services provider’s stock worth $7,177,000 after acquiring an additional 43,385 shares during the last quarter. Swiss National Bank grew its holdings in Amedisys by 1.1% during the third quarter. Swiss National Bank now owns 71,700 shares of the health services provider’s stock valued at $6,697,000 after purchasing an additional 800 shares during the period. Finally, Alpine Associates Management Inc. increased its stake in Amedisys by 46.6% in the third quarter. Alpine Associates Management Inc. now owns 1,033,497 shares of the health services provider’s stock valued at $96,529,000 after purchasing an additional 328,300 shares in the last quarter. Institutional investors and hedge funds own 94.36% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the stock. StockNews.com raised shares of Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Royal Bank of Canada boosted their target price on Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 25th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $101.00 price target on shares of Amedisys in a research report on Thursday, April 25th. Finally, Raymond James reiterated a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $100.80.
Get Our Latest Stock Analysis on AMED
Amedisys Stock Down 5.1 %
NASDAQ:AMED opened at $91.15 on Friday. The company has a market cap of $2.98 billion, a PE ratio of -142.42, a PEG ratio of 2.36 and a beta of 0.84. The stock has a 50-day simple moving average of $93.16 and a 200 day simple moving average of $93.71. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.09. Amedisys, Inc. has a 52-week low of $74.61 and a 52-week high of $97.36.
Amedisys (NASDAQ:AMED – Get Free Report) last posted its quarterly earnings data on Wednesday, April 24th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Amedisys had a negative net margin of 0.91% and a positive return on equity of 12.85%. The company had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. During the same period last year, the company earned $1.00 earnings per share. The firm’s revenue was up 2.7% compared to the same quarter last year. On average, sell-side analysts expect that Amedisys, Inc. will post 4.57 EPS for the current fiscal year.
Amedisys Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Further Reading
Receive News & Ratings for Amedisys Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amedisys and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
